PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

NCT06196736 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT432
EST. COMPLETION2026-09

Conditions

Advanced Urothelial Carcinoma

Interventions

9MW2821Chemotherapy

Study details

SPONSORMabwell (Shanghai) Bioscience Co., Ltd.
START DATE2023-12-29

Related company profiles

Mabwell

688062.SS

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT06196736
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record